The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.

@article{Cooper2004TheEA,
  title={The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.},
  author={N. Cooper and Roberto Stasi and Susanna Cunningham-Rundles and Michael A Feuerstein and John P. Leonard and S. Amadori and James B Bussel},
  journal={British journal of haematology},
  year={2004},
  volume={125 2},
  pages={
          232-9
        }
}
Because of its B-cell depleting effect, rituximab has entered clinical trials in several autoimmune conditions. This study assesses the efficacy and safety of rituximab in 57 adults with chronic immune thrombocytopenic purpura (ITP). All patients had platelet counts < 30 x 10(9)/l, all had received two or more previous ITP treatments and 31 had undergone splenectomy. Patients received rituximab 375 mg/m(2) weekly for 4 weeks. Thirty-one patients (54%) responded, achieving a platelet count >50 x… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 105 CITATIONS

Rituximab in the treatment of autoimmune haematological disorders

St Michael’s
  • 2008
VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights.

  • Frontiers in bioscience : a journal and virtual library
  • 2007
VIEW 15 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Rituximab for the treatment of autoimmune cytopenias.

  • Haematologica
  • 2007
VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2005
2019

CITATION STATISTICS

  • 8 Highly Influenced Citations

  • Averaged 4 Citations per year over the last 3 years

Similar Papers

Loading similar papers…